Kura Oncology (NASDAQ:KURA) reported Q4 EPS of ($0.49), $0.08 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
Kura Oncology (NASDAQ:KURA) reported Q4 EPS of ($0.49), $0.08 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .